How to model for loss of exclusivity and generic entrants
When a pharmaceutical company patents a new drug, the business is granted an exclusive window to sell that product at a premium to recoup R&D costs. Once the patent expires, however, generic manufacturers can enter the market, often triggering a sharp drop in the original product's sales and influencing broader dynamics.
Is your company prepared for the ripple effects of a patent cliff, whether it's your drug or a competitor's? A new report from J+D Forecasting, now part of Evaluate, explores how to factor these market shifts into your forecasting structure.
Download your copy and discover how to adapt your forecasting model to:
Identify all current and future products of interest
Focus on those brands of greatest competitive threat
Tell a clear story of the landscape following a patent expiry.
